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A B S T R A C T
Rotavirus infection remains a great health burden worldwide especially in some developing countries. It causes severe dehydrating diarrhea in infants, young
children, as well as immunocompromised and organ transplanted patients. Viral replication heavily relies on the host to supply nucleosides. Thus, host enzymes
involved in nucleotide biosynthesis represent potential targets for antiviral development. Dihydroorotate dehydrogenase (DHODH) is the rate-limiting enzyme in the
de novo biosynthesis pathway of pyrimidines. In this study, we demonstrated that two speciﬁc DHODH enzyme inhibitors, brequinar (BQR) and leﬂunomide (LFM)
robustly inhibited rotavirus replication in conventional human intestinal Caco2 cell line as well as in human primary intestinal organoids. The antiviral eﬀect is
conserved in both laboratory strain SA11 and rotavirus strain 2011K isolated from clinical sample. Mechanistic study indicated that BQR and LFM exerted their anti-
rotavirus eﬀect through targeting DHODH to deplete pyrimidine nucleotide pool. Therefore, targeting pyrimidine biosynthesis represents a potential approach for
developing antiviral strategies against rotavirus.
1. Introduction
Rotavirus (RV), a member of Reoviridae family, is a non-enveloped
virus which has a double-stranded RNA genome of 11 segments sur-
rounded by three concentric protein layers. It has been reported to
cause estimated 25% of moderate-to-severe illnesses (Kotloﬀ et al.,
2013) and 30% of total diarrheal deaths during the ﬁrst 2 years from
birth (Wang et al., 2016a). The development and deployment of rota-
virus vaccines was a breakthrough in the ﬁght against diarrheal dis-
eases. Two rotavirus vaccines, Rotarix™ and Rotateq, are licensed and
widely available in several countries (Yin et al., 2018). Nevertheless,
due to limited resources, developing countries including India, Nigeria,
Pakistan, Ethiopia and the Democratic Republic of the Congo bear the
major burden of mortality (Groome et al., 2014). In addition, im-
munocompromised patients are also under the risk of RV infection
which would cause remarkable morbidity and mortality (Lee and Ison,
2014; Sugata et al., 2012; Yin et al., 2015c). For the treatment of ro-
tavirus gastroenteritis, intravenous ﬂuid supply has been used for
treatment of dehydration from diarrhea. However, in the severe case of
inpatients and immunocompromised patients who are suﬀering from
prolonged diarrhea and fever, virus-speciﬁc treatment will be expected,
if possible. In fact, there is still no FDA-approved medication available
against rotavirus disease. Therefore, to ensure that the remaining
burden of mortality and morbidity can be fully addressed in the future,
research on the development of novel antiviral strategies is highly
needed.
Cellular nucleotides, composed of purines and pyrimidines, play a
vital role in constituting nucleic acids RNA and DNA. De novo synthesis
and salvage pathway are the two pathways for nucleic acid synthesis in
vivo (Evans and Guy, 2004). Viral replication heavily relies on host
supply of nucleoside biosynthesis. Therefore, host enzymes involved in
nucleoside biosynthesis represent potential targets for antiviral devel-
opment. Ribavirin, the most well-known antiviral drug, is such an in-
hibitor that suppresses guanine biosynthesis via inhibition of cellular
IMP dehydrogenase (IMPDH). Several studies have indicated that de-
pletion of cellular GTP pool is the primary mechanism by which riba-
virin inhibits virus replication (e.g. ﬂaviviruses and hepatitis E virus)
(García et al., 2018; Nicolini et al., 2018). Along this line, we aim to
investigate whether inhibitors of the pyrimidine biosynthesis pathway
could be targeted for potential antiviral development against rotavirus.
Dihydroorotate dehydrogenase (DHODH) is sequentially the fourth
and the rate-limiting enzyme in the de novo biosynthesis pathway of
pyrimidines. It is located in the inner membrane of mitochondria,
where it plays a role of converting dihydroorotate to orotate (Munier-
Lehmann et al., 2013). Then, the multifunctional UMP synthase uses
orotate to produce UMP, one of the essential precursors for synthesis of
all other pyrimidine nucleotides. Several studies have reported that
inhibition of DHODH enzyme suppresses a range of diﬀerent viruses
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replication (Hoﬀmann et al., 2011; Luthra et al., 2018; Tan et al., 2005;
Wang et al., 2011, 2016b).
In this study, we report that brequinar (BQR) and leﬂunomide
(LFM), two DHODH inhibitors, potently inhibit rotavirus replication in
human intestinal cell line as well as three dimensional (3D) cultured
primary intestinal organoids. Mode-of-action studies demonstrate that
their antiviral activity is mainly achieved via the inhibition of DHODH,
resulting in the depletion of intracellular pyrimidine pools. Collectively,
our study has stressed the concept that targeting pyrimidine biosynth-
esis represents a potential approach for antiviral development against
rotavirus.
Fig. 1. BQR and LFM exert potent anti-
viral activity against rotavirus SA11 on
Caco2 cells. Caco2 cells were infected with
SA11 rotavirus. After infection, cells were
treated with various concentrations of BQR
or LFM. (A) qRT-PCR analysis indicated that
BQR (n=6) and LFM (n= 6) exerted po-
tent antiviral eﬀect against rotavirus re-
plication. Data were normalized to house-
keeping genes GAPDH and presented
relative to the control (CTR) (set as 1). Data
represent means ± SEM. *, P < 0.05; **,
P < 0.01. (B) Western blot analysis
showed that BQR (n = 4, 0.05–5 μM) and
LFM (n = 4, 50 μM) inhibited rotavirus
replication. Data represent means ± SEM.
*, P < 0.05. (C) 50% cytotoxic concentra-
tion (CC50) curves of BQR (left panel) and
LFM (right panel) were determined by MTT
assays. (D) The supernatant of each well
was harvested after freeze and thaw for
three times, virus titer from diﬀerent groups
was measured (n = 4. Data represent
means ± SEM. ***, P < 0.001).
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2. Materials and methods
2.1. Reagents
Brequinar (BQR) sodium salt hydrate (Method Detection Limit
[MDL] no. MFCD21363375), leﬂunomide (LFM) (Chemical Abstracts
Service [CAS] no. 75706-12-6), 6-azauracil (6-AU) (MDL no.
MFCD00006456) and uridine (CAS no. 58-96-8), were purchased from
Sigma. All the reagents were dissolved in dimethyl sulfoxide (DMSO).
2.2. Viruses
Simian rotavirus SA11, a broadly used and well-studied laboratory
strain (Cecílio et al., 2012), was gifted by Karen Knipping from Nutricia
Research Utrecht, The Netherland. In the study, rotavirus SA11 was
prepared as described (Knipping et al., 2012). Stool sample collected
from rotavirus infected patient was obtained from the Erasmus MC
biobank, Department of Viroscience, Erasmus Medical Center, Rot-
terdam. This stool sample 2011K was taken during patient diarrhea
period and tested for enterovirus, parechovirus, norovirus genogroups I
and II, rotavirus, adenovirus, astrovirus and sapovirus by PCR. Sample
2011K is only positive to rotavirus and negative to other virus men-
tioned above. Sample information was also described in previous stu-
dies (Corless et al., 2002; Hoek et al., 2013; van Maarseveen et al.,
2010).
2.3. Cell lines and human primary intestinal organoids
Human colon cancer cell line Caco2 and human embryonic kidney
cell line 293T (HEK 293T) were cultured in Dulbecco's modiﬁed Eagle's
medium (DMEM; Lonza, Verviers, Belgium) containing 20% (vol/vol)
heat-inactivated fetal calf serum (FCS, Sigma–Aldrich, St. Louis USA)
and 100 U/ml Penicillin/Streptomycin (P/S, Gibco, Grand Island, USA)
solution. A humidiﬁed incubator was used for cells culturing at 37 °C in
5% CO2. Cells were analyzed by genotyping and conﬁrmed to be my-
coplasma negative.
Human primary small intestinal organoids culture was performed as
described previously (Yin et al., 2015a). Fragments of intestinal biop-
sies or surgically resected intestinal tissues were treated with complete
chelating solution (CCS, MilliQ H2O was supplemented with 1.0 g/L of
Na2HPO4e2H2O, 1.08 g/L of KH2PO4, 5.6 g/L of NaCl, 0.12 g/L of KCl,
15 g/L of Sucrose, 10 g/L of D-Sorbitol and 80 μg/L of DL-dithiothreitol)
followed by 8mM EDTA. Crypts were ﬁnally collected and suspended in
40 μL growth factor reduced phenol-red free Matrigel (Corning, Bed-
ford, USA). Then, they were incubated at 37 °C with 5% CO2 with
culture medium containing CMGF, 2% (vol/vol) of B-27® Supplements
(Gibco, Grand Island, USA), 1% (vol/vol) of N2® Supplements (Gibco,
Grand Island, USA), 500 pg/mL of EGF, 1mM n-Acetyl Cysteine, 10mM
Nicotinamide, 0.5 μM A83-01 (TGF-b inhibitor), 3 μM SB202190 (p38
inhibitor), 20% (vol/vol) of R-Spondin 1 (conditioned medium), 10%
(vol/vol) of Noggin (conditioned medium) and 50% (vol/vol) of Wnt3a
(conditioned medium). Culture medium was refreshed every 2–3 days,
and HIOs were passaged every 6–7 days.
2.4. Inoculation of SA11 rotavirus and clinical derived strain 2011K
Caco2 cells were washed, suspended in T75 ﬂask and subsequently
seeded into a 48-well plate (5× 104 cells/well). Culture medium was
discarded when cell conﬂuence was approximately 80%, and cell
monolayers were washed twice with PBS. 100 μL of serum-free DMEM
medium, then rotavirus (MOI= 0.7) with 5 μg/mL of trypsin (Gibco,
Paisley, UK) were added and incubated at 37 ̊C with 5% CO2 for 60min
for infection, followed by 4 times washing with PBS to remove un-at-
tached viruses Then, cells were incubated with culture medium con-
taining 5 μg/ml of trypsin at 37 °C with 5% CO2.
2.5. Virus production assay
Virus, cell line and HIOs were treated as previous work (Yin et al.,
2015b). In short, caco2 cells were inoculated with SA11 rotavirus
(MOI=0.7) then harvested after 48 h incubation with serum-free
medium to perform assays as followed. In parallel, human primary in-
testinal organoids were infected with 10 times higher concentration of
SA11 rotavirus than cell infection for 1.5 h followed by 4 times washing
with PBS. Afterwards, HIOs with no Matrigel remain were spun down at
500 g for 10min to adhered to the bottom of 24-well plate coated with
Collagen R solution (SERVA, Heidelberg, Germany). Organoids culture
medium was added gently and HIOs were incubated at 37 °C with 5%
CO2. Culture medium and HIOs were harvested respectively after 48 h
to detect and enumerate rotavirus. Virus titers from supernatants were
determined by calculating the log10TCID50/mL in Ma104 cells using the
method developed by Reed and Muench (Reed and Muench, 1938).
2.6. RNA isolation, cDNA synthesis and qRT-PCR
Total RNA was isolated using Macherey-Nagel NucleoSpin® RNA II
Fig. 2. BQR and LFM inhibit the expres-
sion of rotavirus VP6 protein. (A)Indirect
ﬂuorescence microscope analysis of viral
structural protein VP6 (red) upon treatment
with BQR (0.05 μM) and LFM (5 μM).
Nuclei were visualized by DAPI (blue). (B)
The ratio of VP6 positive cells/total cell
number was quantiﬁed (n = 4). Data re-
present means ± SEM. *, P < 0.05.
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kit (Bioke, Leiden, Netherlands) and quantiﬁed using a Nanodrop ND-
1000 (Wilmington, DE, USA). Total RNA reverse transcription was
performed by using a cDNA Synthesis kit (TAKARA BIO INC.) with
random hexamer primers. Real-time PCR reactions (50 °C for 2min,
95 °C for 10min, followed by 50 or 60 cycles of 95 °C for 15 s and 58 °C
for 30 s and 72 °C for 10min) were performed with SYBRGreen-based
real-time PCR (Applied Biosystems®, Austin, USA) according to the
manufacturer's instruction. Glyceraldehyde 3-phosphate dehydrogenase
(GAPDH) gene was used as housekeeping gene. Relative gene expres-
sions were normalized to GAPDH using formula 2-ΔΔCT
(ΔΔCT= ΔCTsample - ΔCTcontrol). Template control and reverse
transcriptase control were included in all RT-qPCR experiments. All
qRT-PCR primers are listed in Supplementary Table 1.
2.7. Quantiﬁcation of rotavirus genome copy numbers
An amplicon of the SA11 (a fragment of VP6 gene from 564 to 718)
was cloned into the pCR2.1-TOPO vector (Invitrogen, San Diego, CA) to
generate a template for quantifying rotavirus genome copy number.
The plasmid was extracted by Quick Plasmid Miniprep Kit (Invitrogen,
Lohne, Germany) following manufacturer's instructions. A series of di-
lutions (from 10−2 to 10−10) were prepared and then were ampliﬁed
and quantiﬁed by qRT-PCR to generate a standard curve. This standard
curve was generated by plotting the log copy number versus the cycle
threshold (CT) value (Fig. S1). Copy numbers were calculated by using
the following equation: Copy number (molecules/μl)= [concentration
(ng/μl)× 6.022× 1023 (molecules/mol)]/[length of amplicon×640
(g= /mol)× 109 (ng/g).
Fig. 3. BQR and LFM exert potent antiviral activity against rotavirus SA11 on human intestinal organoids. (A) Representative microscopy image of cultured
human small intestinal organoids. (B) BQR (n = 6) as well as LFM (n = 6) inhibit SA11 replication and virus production after 48 h incubation. The relative rotavirus
RNA and genomic copy number were analyzed by qRT-PCR. Data represent means ± SEM. *, P < 0.05; **, P < 0.01 (Data of standard curve is in Supplementary
Fig. S1).
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Fig. 4. Microscopy image analysis indicated that BQR and LFM exert potent antiviral activity against rotavirus SA11 on human intestinal organoids
(HIOs). (A) Microscopy image analysis of HIOs treated with 5 μM BQR and 50 μM LFM. (B) Microscopy image analysis of HIOs infected by rotavirus SA11 and treated
with CTR, 5 μM BQR or 50 μM LFM. (C) Scoring of proportion of deteriorated HIOs in diﬀerent random visions, n = 6. Data represent means ± SEM. **, P < 0.01.
(D) 5 μM BQR and 50 μM LFM inhibited rotavirus SA11 replication on HIOs. Rotavirus structural protein VP6 (red). Nuclei were visualized by DAPI (blue).
S. Chen, et al. Antiviral Research 167 (2019) 35–44
39
2.8. Determination of compromised organoids scoring
The scoring process was performed as previously (Grabinger et al.,
2014). In short, minimum of 100 organoids were counted after 3 days
of passaging. After 1.5 h incubation with SA11 rotavirus, HIOs were
cultured in matrigel and treated with diﬀerent agents for 48 h, and HIOs
were counted and deﬁned as viable or dead via their morphological
appearance in the optimal microscope (Axiovert 40 CFL, Zeiss, Ober-
kochen, Germany) in at least three random visions in diﬀerent parallel
wells, the description of this scoring system is showed in Fig. S3. The
proportion of deteriorated organoids was calculated as (viable/total) %.
2.9. Gene knockdown assays
Lentiviral shRNA vectors, targeting dihydroorotate dehydrogenase
(DHODH) gene or non-targeted control lentivirus were produced in
293T cells as previous work (Qu et al., 2018). Caco2 cells were in-
oculated with lentivirus to generate stable gene knockdown cells. Cells
were subsequently selected with 5 μg/mL puromycin (Sigma). After
pilot study, two shRNA vectors exerting optimal gene knockdown were
selected. Knockdown and control Caco2 cells were incubated with ro-
tavirus as described above. All shRNA primers were listed in
Supplementary Table 2.
2.10. Western blot assay
Lysed cells were subjected to SDS-PAGE, and proteins were trans-
ferred to PVDF membrane (Immobilon-FL). DHODH (ab 54621, 1:1000,
mouse monoclonal, Abcam), SA11 rotavirus VP4 (1:1000, HS-2, mouse
monoclonal; provided by professor Harry Greenberg, Stanford
University School of Medicine, USA) was detected by western blot
analysis and β-actin protein was detected as loading control (sc-47778,
1:1000, mouse monoclonal; Santa Cruz). The intensity of the im-
munoreactive bands of blotted protein was quantiﬁed by the Odyssey
V3.0 software.
2.11. Immunoﬂuorescence analysis
After rotavirus infection and BQR treatment, HIOs were harvested
and ﬁxed in 4% paraformaldehyde in PBS at 4 °C for 10 min. Fixed HIOs
were added into the CytoSpin II Cytocentrifuge (Shandon Scientiﬁc Ltd,
Runcorn, England), then spined down at 1000 rpm for 2 min. The slides
containing HIOs were rinsed 3 times with PBS for 5 min each, followed
by treatment with 0.1% (vol/vol) Tritonx100 for 4 min. Subsequently,
the slides were twice rinsed with PBS for 5 min, followed by incubation
with milk-tween-glycine medium (0.05% tween, 0.5% skim milk and
0.15% glycine) to block background staining for 30 min. Slides were
incubated in a humidity chamber with anti-rotavirus antibodies (1:250,
mouse monoclonal; Abcam) diluted in milk-tween-glycine medium at
4 °C overnight. Slides were washed 3 times for 5 min each in PBS prior
to 1 h incubation with 1:1000 dilutions of the anti-mouse IgG (H+L,
Alexa Fluor® 594) secondary antibody. Nuclei were stained with DAPI
(4, 6-diamidino-2-phenylindole; Invitrogen). Images were detected
using EVOS FL cell imaging system (Thermo Fisher).
2.12. MTT assay
The CC50 values of BQR and LFM (1613 μM for BQR and 372 μM for
LFM) were determined by MTT assay (Fig. 1C) as previous study (Qu
et al., 2018). Approximately 1× 104 Caco2 cells were seeded per well
in 96-well plate. After 48 h, cells were incubated with 10 μL 5mg/ml
MTT for 3 h, then replaced with 100ml dimethyl sulfoxide (DMSO)
medium (Sigma). Absorbance (490 nm) was analyzed accordingly.
2.13. Statistics
All numerical results were performed at least two technical re-
plicates in twice biological replicates and are reported as Mean ± SEM.
The statistical signiﬁcance of diﬀerences between means was assessed
with the Mann-Whitney test (GraphPad Prism 5; GraphPad Software
Inc., La Jolla, CA). The threshold for statistical signiﬁcance was deﬁned
as P≤ 0.05.
Fig. 5. BQR and LFM showed antiviral
eﬀect against clinical-derived rotavirus
strains. (A) qRT-PCR analysis indicated
that BQR (n= 6) and LFM (n= 6) exerted
strong antiviral eﬀect against rotavirus
2011K. Data were normalized to house-
keeping genes GAPDH and are presented
relative to the control (CTR) (set as 1). Data
represent means ± SEM. *, P < 0.05; **,
P < 0.01. (B) Virus titer of rotavirus 2011K
were measured upon BQR and LFM treat-
ment respectively (n = 4). Data represent
means ± SEM. ***, P < 0.001.
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3. Result
3.1. BQR and LFM potently inhibit the replication of SA11 and patient-
derived rotavirus strain 2011K
BQR is an immunosuppressive and antiproliferative compound
which has been evaluated in multiple clinical trials as a potential
treatment for cancer (Madak et al., 2017; Makowka et al., 1993). Si-
milarly, LFM is also an immunosuppressive drug used in active mod-
erate-to-severe rheumatoid arthritis and psoriatic arthritis (Davis et al.,
1996). So we tried to investigate whether these two inhibitors of the
pyrimidine biosynthesis pathway have potential anti-rotavirus eﬀect.
After infection by simian rotavirus SA11, Caco2 cells were treated with
various concentrations of BQR and LFM for 48 h. BQR and LFM potently
inhibited SA11 rotavirus replication in a dose-dependent manner as
measured in both RNA and protein levels (Fig. 1A and B), while cell
viability was not aﬀected (Fig. 1C). The IC50 values of BQR and LFM are
0.04917 μM and 48.98 μM respectively, while the CC50 values are
1613 μM and 372 μM, indicating a high speciﬁcity of these two
compounds on rotavirus (Fig. 1C and Fig. S2). Consistently, SA11 ro-
tavirus titer was also signiﬁcantly decreased by BQR and LFM treatment
(Fig. 1D). Indirect ﬂuorescence microscopy analysis further conﬁrmed
that BQR and LFM could inhibit rotavirus replication (Fig. 2A and B).
3D cultured primary human intestinal organoids (HIO) represent state-
of-art model for investigating intestinal physiology and pathology.
Therefore, we further tested the antiviral activity of BQR and LFM
based on the HIO model. Importantly, BQR and LFM reduced the levels
of cellular viral RNA and inhibited virus production signiﬁcantly, while
no cytotoxicity eﬀects were observed (Fig. 3A and B, Fig. S3A). For
instance, with 5 μM of BQR, cellular viral RNA was decreased by 65%
(n= 6, p < 0.01), and virus production was inhibited by 76% (n=6,
p < 0.01). Since rotavirus infection causes pathological and morpho-
logical changes on organoids, we randomly selected three scopes and
quantiﬁed the proportion of compromised organoids upon diﬀerent
treatments. Both BQR and LFM could strongly decrease the proportion
of compromised organoids (Fig. 4A–C). This notion was further sup-
ported by the evidence that BQR and LFM led to the decreased levels of
rotavirus VP6 protein (Fig. 4D). Next, we expand our study to patient-
Fig. 6. BQR and LFM exert its anti-rota-
virus eﬀect through targeting DHODH to
deplete pyrimidine nucleotide pool. (A)
qRT-PCR and western blot analysis con-
ﬁrmed the knockdown of DHODH in Caco2
cells (n = 9). Data represent
means ± SEM. ***, P < 0.001. (B)
Knockdown of DHODH signiﬁcantly in-
hibits SA11 rotavirus replication in Caco2
cells (n = 6). Data represent
means ± SEM. **, P < 0.01. (C) Anti-
rotavirus eﬀect of BQR and LFM was par-
tially blocked in two clones of DHODH
knockdown cells (n = 6). Data represent
means ± SEM. *, P < 0.05. (D)
Supplementation of exogenous uridine at-
tenuates the anti-rotavirus eﬀect of BQR
and LFM in Caco2 cells (n = 6). Data re-
present means ± SEM. **, P < 0.01.
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derived rotavirus strain 2011K. Consistently, BQR and LFM profoundly
inhibited virus replication of this rotavirus strain (Fig. 5). Collectively,
these results demonstrated that BQR and LFM could potently inhibit
rotavirus replication.
3.2. BQR and LFM, two DHODH inhibitors, inhibit rotavirus replication
through depletion of the cellular pyrimidine nucleotide pool
Classically, BQR and LFM are two well-established DHODH in-
hibitors. Upon inhibition of DHODH, cellular pyrimidine biosynthesis
pathway will be blocked, resulting in the depletion of pyrimidine nu-
cleotide pool. To investigate whether these two compounds exert a si-
milar mode-of-action against rotavirus, we employed both BQR and
LFM for further mechanistic study. We ﬁrst used an RNAi-based loss-of-
function assay to study the role of DHODH. Two successful knock-down
clones were conﬁrmed by both qRT-PCR and western blot (Fig. 6A).
And the silencing of DHODH resulted in compromised rotavirus re-
plication (Fig. 6B). The speciﬁc eﬀect was further conﬁrmed when we
added BQR and LFM to DHODH knockdown or control cell lines in-
fected with SA11. Knockdown of DHODH abrogated the anti-rotavirus
eﬀect rate of BQR from 53% to 37% and 38% respectively. As for LFM,
the eﬀect rate was decreased from 72% to 50% on both knockdown cell
lines (Fig. 6C). To further validate whether the antiviral eﬀect of BQR
and LFM was achieved via the depletion of pyrimidine pool, exogenous
uridine was supplemented to cell culture medium. Of note, supple-
mentation of pyrimidine dose-dependently abolished the anti-rotavirus
eﬀect of BQR and LFM. At the concentration of 2000 μM, BQR and LFM-
related anti-rotavirus eﬀect was totally abolished (Fig. 6D). Taken to-
gether, these results indicated that BQR and LFM exerts their anti-ro-
tavirus eﬀect through targeting DHODH to deplete pyrimidine nucleo-
tide pool. Orotidine 5′-monophosphate decarboxylase (ODCase) serves
as the downstream enzyme of DHODH, which catalyzes OMP to UMP.
6-azauracil (6-AU), a potent inhibitor of ODCase, was evaluated for its
potential eﬀect on rotavirus replication. Consistently, 6-AU also inhibits
rotavirus replication (Fig. 7A). Conceptually, targeting pyrimidine
biosynthesis represents a potential approach for antiviral development
against rotavirus.
4. Discussion
Though rotavirus vaccine has been introduced, and the vaccine re-
markably reduced the burden of rotavirus gastroenteritis in many de-
veloped countries, however, due to prevalence and diversity of the
virus, one third to half of the children are still suﬀering from
vaccination failure in some developing countries (Macartney et al.,
2000). Antiviral treatment shall serve as complement to vaccine. A drug
repurposing approach oﬀers many advantages for the identiﬁcation of
new antiviral strategies over the development of new drugs, since safety
and pharmacology in humans are already well known. Therefore, if a
drug, currently in clinical use, demonstrates considerable antiviral ac-
tivity against rotavirus, there should be great potential to expand its
application to combating rotavirus infection.
Of note, BRQ and LFM are two well-known immunosuppressive
agents (Batt, 1999). As for LFM, it was reported as immunosuppressive
therapy for bone marrow (Avery et al., 2004) and renal (Chon and
Josephson, 2011) transplantation. Accumulating evidence indicated
that organ transplant patients irrelevant to their ages are more vul-
nerable to rotavirus infection. Thus, the potential clinical prospects of
BQR and LFM or their analogues may be of achieving “one stone two
birds” eﬀects: exerting immunosuppressive function and anti-rotavirus
eﬀect at the same time. Of note, BQR was reported to have some side
eﬀects, such as leukocytopenia,thrombocytopenia, reduced body
weight gain or body weight loss, thymic atrophy, cellular depletion of
bone marrow and splenic white pulp, and villous atrophy in jejunum
(Pally et al., 1998). Similarly, LFM also has side eﬀects, including
gastrointestinal symptoms, rash or allergic reactions and alopecia
(Emery et al., 2000; Mladenovic et al., 1995; Smolen et al., 1999;
Strand et al., 1999). These kinds of clinical observation are compre-
hensible based on the fact that all drugs come with side eﬀects. Im-
portantly, the drug dosages of both drugs used in our study for in-
hibition of rotavirus are much lower than their previous clinical trial
dosages (Maroun et al., 1993; Natale et al., 1992; Smolen et al., 1999).
This might make BQR or LFM a preferable option for treating rotavirus
infection, achieving high eﬃcacy with less side eﬀects. In addition,
pyrimidine biosynthesis (Fig. 7B) represents a potential host pathway
for novel antiviral drug development. These speciﬁc inhibitors of this
pathway may represent as a starting point for the development of ef-
ﬁcient anti-rotavirus drugs with more broad applications.
Intestinal carcinoma-derived cell lines such as Caco2 cell line are
widely used as in vitro model to investigate rotavirus infection (Cuadras
et al., 2002; Frias et al., 2012). Compared to such two-dimensional (2D)
single cell type culture systems, the three-dimensional (3D) model of
human primary intestinal organoids surpass 2D models by cell diversity
and spatial structure on rotavirus infection (Yin et al., 2015a). Speci-
ﬁcally, these primary intestinal organoids consist of many un-
diﬀerentiated and heterogeneous cell types with similar functions as in
the organ/tissue of origin (Sato and Clevers, 2012, 2013; Sato et al.,
2009, 2011), including enterocytes, enteroendocrine cells, goblet cells,
Fig. 7. Depleting pyrimidine nucleotide pool inhibits rotavirus replication. (A) qRT-PCR analysis showed that 6-AU, a speciﬁc inhibitor of ODCase, inhibited
rotavirus replication (n = 6). Data represent means ± SEM. *, P < 0.05. (B) Schematic overview of de novo pyrimidine biosynthesis pathway.
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Paneth cells and stem cells (Saxena et al., 2015). We have validated our
results observed in conventional cell culture model also in the primary
human organoids. Moreover, the use of rotavirus strains isolated from
clinical samples leads our study one step closer to clinical therapy
against rotavirus infection.
Nucleotides play an important role in host cell metabolism and are
essential for virus infection. Many inhibitors targeting de novo pyr-
imidine biosynthesis (Fig. 7B) have been well studied on dengue virus,
HBV, HEV and other virus infection models (Beardsley et al., 1989;
Greene et al., 1995; Hoppe-Seyler et al., 2012; Nelson et al., 1975; Qing
et al., 2010; Silva et al., 1997; Wang et al., 2011, 2016b). In this study,
we demonstrated that both BQR and LFM, inhibitors of DHODH en-
zyme, have potent antiviral activity against rotavirus infection. Me-
chanistic study demonstrated that BQR and LFM exert their anti-rota-
virus eﬀect through targeting DHODH to deplete pyrimidine nucleotide
pool. Therefore, targeting pyrimidine biosynthesis represents a poten-
tial approach for developing antivirals against rotavirus.
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